For most parents, hearing their baby’s heartbeat for the first time is pure joy. For families of children born with congenital heart disease, it can also mark the start of a long and uncertain road. Heart defects are the most common type of birth defect, with a baby being born in the U.S. every 15 minutes with a congenital heart defect (Source). For children with the most severe forms, childhood can become a cycle of hospital stays, slow recoveries and repeat trips to the operating room.
A partnership among some of the nation’s leading medical and research institutions hopes to change that story.
On October 21, Boston Children’s Hospital, the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), NTT Research and Brigham and Women’s Hospital announced THUMPIN’ (Tissue-engineered Hearts Using Multimodal Printing in Newborns). The research effort, led by Boston Children’s, is supported by a contract of up to $29.6 million over as many as five years from the Advanced Research Projects Agency for Health (ARPA-H), along with other funders. Its goal is to create living heart tissue and heart parts, and ultimately a complete, working heart, for infants and young children with congenital heart disease.
Why children face so many surgeries
Today, surgeons can repair many heart defects, but the repairs don’t grow the way a child does. As a child gets bigger, a repair that worked well in infancy may need to be redone, sometimes again and again. Dr. Pedro del Nido, chair of Cardiac Surgery at Boston Children’s Hospital, noted that infants with the most serious defects may undergo one operation after another as they grow, and some eventually run out of available options.
A living solution that grows with the child
That is where THUMPIN’ comes in. Instead of relying on materials that stay the same size, researchers are working to build heart tissue from living cells, tissue designed to grow, function and adapt alongside the child. Over the course of the project, the team plans to engineer heart valves, blood vessel grafts, patches for heart muscle, parts of the heart’s electrical system, single ventricles and, eventually, an entire heart.
Dr. del Nido said that living tissue able to grow with an infant could fundamentally change the path these children face. The project’s lead scientist, Dr. Kit Parker of Harvard SEAS and Boston Children’s, described the goal as living hearts and heart parts that develop and adapt as a child grows up.
A team effort
The project brings together experts in pediatric heart surgery, stem cell biology, tissue engineering, 3D manufacturing and computer modeling. NTT Research brings its expertise in building computer models that help physicians understand and treat heart disease. Dr. Joe Alexander, director of the NTT Research BioMedical Engineering Innovation Lab, said the team’s work is aimed at a future where young patients may receive “living heart replacements that can grow and adapt throughout their lives.”
The road ahead
This is careful, step-by-step science. The work will move from laboratory testing to studies in large animals, while the team builds the manufacturing, safety and regulatory groundwork needed to seek U.S. Food and Drug Administration approval for the first studies in people. Manufacturing will be led in partnership with Landmark Bio.
For families who have watched their children face surgery after surgery, the promise is profound: a heart repair that doesn’t need replacing, because it grows up right along with them.
